ENFORTUMAB VEDOTIN-EJFV for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 68 adverse event reports in the FDA FAERS database where ENFORTUMAB VEDOTIN-EJFV was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for ENFORTUMAB VEDOTIN-EJFV
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 560 | 15.0% | 53 | 172 |
| Malignant neoplasm progression | 410 | 11.0% | 137 | 79 |
| Neuropathy peripheral | 410 | 11.0% | 22 | 61 |
| Fatigue | 281 | 7.5% | 33 | 79 |
| Pruritus | 260 | 7.0% | 25 | 95 |
| Diarrhoea | 257 | 6.9% | 46 | 114 |
| Death | 238 | 6.4% | 238 | 46 |
| Decreased appetite | 230 | 6.2% | 34 | 95 |
| Off label use | 193 | 5.2% | 28 | 48 |
| Alopecia | 185 | 5.0% | 19 | 48 |
| Nausea | 168 | 4.5% | 18 | 79 |
| Skin disorder | 157 | 4.2% | 26 | 80 |
| Pyrexia | 156 | 4.2% | 32 | 94 |
| Hyperglycaemia | 148 | 4.0% | 30 | 77 |
| Taste disorder | 142 | 3.8% | 12 | 40 |
Other Indications for ENFORTUMAB VEDOTIN-EJFV
Transitional cell carcinoma (1,179)
Product used for unknown indication (1,061)
Bladder cancer (530)
Transitional cell carcinoma metastatic (390)
Ureteric cancer (106)
Malignant neoplasm of renal pelvis (103)
Metastatic carcinoma of the bladder (96)
Transitional cell cancer of the renal pelvis and ureter (58)
Bladder cancer stage iv (24)
Metastases to lymph nodes (23)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
GEMCITABINE\GEMCITABINE (68)